Marinus Pharmaceuticals Net Worth
Marinus Pharmaceuticals Net Worth Breakdown | MRNS |
Marinus Pharmaceuticals Net Worth Analysis
Marinus Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Marinus Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Marinus Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Marinus Pharmaceuticals' net worth analysis. One common approach is to calculate Marinus Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Marinus Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Marinus Pharmaceuticals' net worth. This approach calculates the present value of Marinus Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Marinus Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Marinus Pharmaceuticals' net worth. This involves comparing Marinus Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Marinus Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Marinus Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Marinus Pharmaceuticals' net worth research are outlined below:
| Marinus Pharmaceuticals generated a negative expected return over the last 90 days | |
| Marinus Pharmaceuticals has high historical volatility and very poor performance | |
| Marinus Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Marinus Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 30.99 M. Net Loss for the year was (141.41 M) with loss before overhead, payroll, taxes, and interest of (55.94 M). | |
| Marinus Pharmaceuticals currently holds about 168.25 M in cash with (118 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.52, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Marinus Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 83.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: US1.86 Thats What Analysts Think Marinus Pharmaceuticals, Inc. Is Worth After Its Latest Results |
Marinus Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Marinus Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Marinus Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Marinus Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Marinus Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Marinus Pharmaceuticals backward and forwards among themselves. Marinus Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Marinus Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Millennium Management Llc | 2024-06-30 | 718.6 K | Ikarian Capital, Llc | 2024-09-30 | 706.2 K | Lion Point Capital, Lp | 2024-09-30 | 693.8 K | Goldman Sachs Group Inc | 2024-06-30 | 582.1 K | Geode Capital Management, Llc | 2024-09-30 | 568.5 K | Renaissance Technologies Corp | 2024-09-30 | 501.9 K | Susquehanna International Group, Llp | 2024-06-30 | 501.8 K | Assenagon Asset Management Sa | 2024-09-30 | 444.2 K | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 414.3 K | Franklin Resources Inc | 2024-09-30 | 4.7 M | Tang Capital Management Llc | 2024-09-30 | 4.7 M |
Follow Marinus Pharmaceuticals' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 17.94 M.Market Cap |
|
Project Marinus Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.83) | (0.87) | |
| Return On Capital Employed | (1.01) | (1.06) | |
| Return On Assets | (0.83) | (0.87) | |
| Return On Equity | (8.43) | (8.01) |
When accessing Marinus Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Marinus Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Marinus Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Marinus Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Marinus Pharmaceuticals. Check Marinus Pharmaceuticals' Beneish M Score to see the likelihood of Marinus Pharmaceuticals' management manipulating its earnings.
Evaluate Marinus Pharmaceuticals' management efficiency
Marinus Pharmaceuticals has return on total asset (ROA) of (0.5775) % which means that it has lost $0.5775 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (29.8655) %, meaning that it created substantial loss on money invested by shareholders. Marinus Pharmaceuticals' management efficiency ratios could be used to measure how well Marinus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.87 in 2024. Return On Capital Employed is likely to drop to -1.06 in 2024. At this time, Marinus Pharmaceuticals' Non Current Assets Total are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 9.2 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 778 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.31 | 0.30 | |
| Tangible Book Value Per Share | 0.31 | 0.30 | |
| Enterprise Value Over EBITDA | (4.57) | (4.80) | |
| Price Book Value Ratio | 34.85 | 36.59 | |
| Enterprise Value Multiple | (4.57) | (4.80) | |
| Price Fair Value | 34.85 | 36.59 | |
| Enterprise Value | 574 M | 602.7 M |
Leadership effectiveness at Marinus Pharmaceuticals is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Enterprise Value Revenue 1.0088 | Revenue 30.3 M | Quarterly Revenue Growth 0.325 | Revenue Per Share 0.539 | Return On Equity (29.87) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Marinus Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Marinus Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Marinus Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Marinus Pharmaceuticals time-series forecasting models is one of many Marinus Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Marinus Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Marinus Pharmaceuticals Earnings per Share Projection vs Actual
Marinus Pharmaceuticals Corporate Management
| MBA CMA | CFO Treasurer | Profile | |
| Christina Shafer | Chief Officer | Profile | |
| Joseph MD | Chief Officer | Profile | |
| Thomas Lyons | Chief Officer | Profile | |
| Sasha Ellis | VP Relations | Profile | |
| Lisa Lejuwaan | VP Sales | Profile | |
| Dayong Li | Senior Biometrics | Profile |
Additional Tools for Marinus Stock Analysis
When running Marinus Pharmaceuticals' price analysis, check to measure Marinus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marinus Pharmaceuticals is operating at the current time. Most of Marinus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Marinus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marinus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Marinus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.